19064-64-3Relevant articles and documents
THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF
-
Paragraph 00281; 00411, (2020/01/08)
Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.
Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors
Liscio, Paride,Carotti, Andrea,Asciutti, Stefania,Karlberg, Tobias,Bellocchi, Daniele,Llacuna, Laura,Macchiarulo, Antonio,Aaronson, Stuart A,Schüler, Herwig,Pellicciari, Roberto,Camaioni, Emidio
supporting information, p. 2807 - 2812 (2014/04/17)
Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4] triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.
6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
-
, (2008/06/13)
8-Methyl-1,2,4-triazolo[4,3-b]pyridazines having a hydroxyalkylamino substituent at the 6-position are described herein. The compounds involved are useful as bronchodilator agents and they are prepared by the reaction of 6-chloro-8-methyl-1,2,4-triazolo[4,3-b]-pyridazine with an appropriate amino alcohol.